 The outcomes associated with ISR highlight the fact that this is by no means a benign process and studies report MI rates as high as 19.4 with one study demonstrating a total rate of death or nonfatal MI of 3.5. In addition, ISR presenting as acute coronary syndrome ACS has an independent effect on major adverse cardiac events. The emergence of fully bioresorbable vascular scaffolds BVS has provided an exciting alternative to combat the long-term structural and functional effects on the coronary vessel seen with implantation of a permanent metal scaffold, regardless of the drug coating. Initial studies have demonstrated the non-inferiority of BVS compared to contemporary DES in regards to death, MI, and MACE. In addition, intravascular imaging has confirmed complete resorbtion of the BVS by 3 years time. The long-term benefits of such technology have yet to be fully assessed. However, based on literature outlining the complicated course of ISR in short-term and that seen in the bare metal stent era, it is projected that complete resorbtion of the vascular scaffold should improve long-term outcomes of patients with ischemic heart disease. 